Clinical aspects of cell death in breast cancer: The polyamine pathway as a new target for treatment

Endocrine-Related Cancer

Volumn 6, Issue 1, 1999, Pages 69-73

  Davidson, N E ^a   Hahm, H A ^a   McCloskey, D E ^b   Woster, P M ^c   Casero Jr , R A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; N1,N11 DIETHYLNORSPERMINE; N1,N12 DIETHYLSPERMINE; POLYAMINE; POLYAMINE DERIVATIVE; SPERMINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL;

ACETYLTRANSFERASES; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FEMALE; HUMANS; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; POLYAMINES; SPERMINE; TUMOR CELLS, CULTURED;

EID: 0032947019     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060069     Document Type: Article

References (23)

1. 1-bis(ethyl) spermine homologues against human MALME-3 melanoma xenografts. Cancer Research 52 2424-2430.
2. 11-diethylnorspermine administered by multiple injection or continuous infusion. Clinical Cancer Research 1 847-857.
3. Brüne B, Hartzell P, Nicotera P & Orrenius S 1991 Spermine prevents endonuclease activation and apoptosis in thymocytes. Experimental Cell Research 195 323-329.
4. 1-acetyltransferase -the turning point in polyamine metabolism. FASEB Journal 7 653-661.
5. Casero RA, Bergeron RJ & Porter CW 1984 Treatment with α-difluoromethylornithine plus a spermidine analog leads to spermine depletion and growth inhibition in cultured L1210 leukemia cells. Journal of Cellular Physiology 121 476-482.
6. Casero RA, Ervin SJ, Celano P, Baylin SB & Bergeron RJ 1989 Differential response to treatment with bis(ethyl)polyamine analogues between human small cell lung carcinoma and undifferentiated large cell lung carcinoma in culture. Cancer Research 49 639-643.
7. Chang BK, Porter CW & Bergeron RJ 1991 Cellular responses to polyamine analogues and inhibitors in human pancreatic adenocarcinoma cell lines. Journal of Cellular Pharmacology 2 133-137.
8. 11 diethylnorspermine in patients with advanced malignancy. Investigational New Drugs 15 227-234.
9. Danzin C, Bey P, Schirlin D & Claverie N 1982 α-Monofluoromethyl and difluoromethyl putrescine as ornithine decarboxylase inhibitors: in vitro and in vivo biochemical properties. Biochemical Pharmacology 31 3871-3878.
10. 12-bis(ethyl)spermine. Cancer Research 53 2071-2075.
11. 11-diethylnorspermine (DENSpm) in patients with non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology 17 190A.
12. Ha HC, Woster PM, Yager JD & Casero RA Jr 1997 The role of polyamine catabolism in polyamine analogue-induced programmed cell death. Proceedings of the National Academy of Sciences of the USA 94 11557-11562.
13. McCloskey DE, Casero RA Jr, Woster P & Davidson NE 1995 Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. Cancer Research 55 3233-3236.
14. McCloskey DE, Yang J, Woster PM, Davidson NE & Casero RA Jr 1996 Polyamine analogue induction of programmed cell death in human lung tumor cells. Clinical Cancer Research 2 441-446.
15. Mamont PS, Duchesne MC, Grove J & Bey P 1978 Anti-proliferative properties of DL-α-difluoromethylornithine in cultured cells. A consequence of irreversible inhibition of ornithine decarboxylase. Biochemical and Biophysical Research Communications 81 58-66.
16. Manni A 1994 The role of polyamines in the hormonal control of breast cancer cell proliferation. Cancer Treatment Reviews 71 209-225.
17. Marton LJ & Morris DR 1987 Molecular and cellular functions of the polyamines. In Inhibition of Polyamine Metabolism: Biological Significance and Basis for New Therapies, pp 79-105. Eds PP McGann, AE Pegg & A Sjoerdsma. New York: Academic Press.
18. Marton LJ & Pegg AE 1995 Polyamines as targets for therapeutic interventions. Annual Review of Pharmacology and Toxicology 35 55-91.
19. Porter CW & Sufrin J 1986 Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. Anticancer Research 6 525-542.
20. Porter CW & Janne J 1987 Modulation of antineoplastic drug action by inhibitors of polyamine biosynthesis. In Inhibition of Polyamine Metabolism: Biological Significance and Basis for New Therapies, pp 203-248. Eds PP McGann, AE Pegg & A Sjoerdsma. New York: Academic Press.
21. Porter CW, McManis J, Casero RA & Bergeron RJ 1987 The relative abilities of bis(ethyl) derivatives of putrescine, spermidine, and spermine to regulate polyamine biosynthesis and inhibit cell growth. Cancer Research 47 2821-2825.
22. 1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Research 51 3715-3720.
23. 1-acetyl-transferase (SSAT) and as potential antitumor agents. Journal of Medicinal Chemistry 36 2998-3004.